Guidelines for veterinarians

Infection with *Ehrlichia canis* (Ehrlichiosis)

Version 1.0 – Approved 24/02/2021

Purpose

This information is intended to help veterinarians diagnose and manage cases of canine monocytic ehrlichiosis.

Infection with *Ehrlichia canis* (*E. canis*) is a notifiable animal disease in the Northern Territory, and any person who suspects or confirms a case must report it to the Emergency Animal Disease Watch Hotline on 1800 675 888.

Contents

<table>
<thead>
<tr>
<th>Nature of the disease</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susceptible species</td>
<td>2</td>
</tr>
<tr>
<td>Clinical signs</td>
<td>2</td>
</tr>
<tr>
<td>Laboratory abnormalities</td>
<td>2</td>
</tr>
<tr>
<td>Differential diagnosis</td>
<td>3</td>
</tr>
<tr>
<td>Disease progression</td>
<td>3</td>
</tr>
<tr>
<td>Notification</td>
<td>3</td>
</tr>
<tr>
<td>Sample collection and testing</td>
<td>3</td>
</tr>
<tr>
<td>Interpretation of results</td>
<td>4</td>
</tr>
<tr>
<td>Case management</td>
<td>4</td>
</tr>
<tr>
<td>Treatment</td>
<td>4</td>
</tr>
<tr>
<td>Response to treatment</td>
<td>5</td>
</tr>
<tr>
<td>Additional recommendations</td>
<td>5</td>
</tr>
<tr>
<td>Movement controls</td>
<td>5</td>
</tr>
<tr>
<td>Prevention</td>
<td>6</td>
</tr>
</tbody>
</table>

Acknowledgements: The Department of Industry, Tourism and Trade wishes to acknowledge the assistance and expertise of Emeritus Professor Peter Irwin of the School of Veterinary Medicine, Murdoch University, in the preparation of these guidelines. Information regarding clinical diagnosis, laboratory abnormalities, disease progression and treatment has been generously provided by Professor Irwin.

Background

*Ehrlichia canis* (*E. canis*) is an obligate intracellular rickettsia-like bacterium transmitted by the brown dog tick (*Rhipicephalus sanguineus*), which causes a severe and potentially life-threatening tick fever disease of dogs called canine monocytic ehrlichiosis (CME). The disease occurs worldwide, particularly in tropical and subtropical regions. It was first detected in Australia in May 2020, and to date has been detected in multiple locations across the Northern Territory (NT) and northern Western Australia.

In rare cases, people may become infected with *E. canis* after being bitten by an infected brown dog tick.
**Nature of the disease**

The brown dog tick is widely distributed worldwide, including Australia, and acts as the primary vector of *E. canis*, spreading the pathogen between hosts during blood meals. The tick retains the pathogen through its life stages (transstadial transmission) and can infect hosts in both nymphal and adult stages.

Brown dog ticks use canine species as a primary host, and as such, CME is predominately associated with dogs. Unexposed ticks acquire the organism after feeding on an infected dog, then transmit the infection to other dogs during successive life stages. *E. canis* can be transmitted from infected ticks to uninfected dogs within a few hours of attachment\(^1\). The organism can also be transmitted through blood transfusions.

*E. canis* infection in dogs may be referred to as canine monocytic ehrlichiosis (CME), canine tropical pancytopenia, tracker dog disease, canine haemorrhagic fever and canine typhus.

**Susceptible species**

Domesticated or wild animals in the family *Canidae* including dogs and foxes are susceptible to *E. canis* infection. It is plausible that the dingo is a suitable host for *R. sanguineus* and is susceptible to infection by *E. canis*. The pathogenicity and virulence of an *E. canis* infection in dingoes is not known but is likely to be similar to disease seen in domestic dogs or other canids.

Several published reports suggest cats may also become infected, though the natural transmission pathway has not been established and infection is considered uncommon.

Infected dogs do not transmit *E. canis* to people. In rare cases, people may become infected with *E. canis* after being bitten by an infected brown dog tick. There have been no reported cases of infection with *E. canis* in humans in Australia.

**Clinical signs**

The disease is recognised from experimental studies to develop through three phases; acute, sub-clinical, and chronic/end stage, however the phase of infection may not be apparent based on clinical signs alone. In practice veterinarians will encounter dogs showing a range of signs, from none in the sub-clinical phase to the following, in approximate order of frequency:

1. Fever
2. Lethargy
3. Anorexia
4. Epistaxis
5. Petechiae & ecchymosis
6. Lymphadenomegaly
7. Splenomegaly
8. Oedema
9. Muscle pain
10. Vestibular disease
11. Hyphema, uveitis & retinal haemorrhages
12. Corneal oedema
13. Weight loss
14. Seizures
15. Polyarthritis

Concurrent infection with other tick fever agents such as *Anaplasma platys* and *Babesia (canis) vogeli* are common. Infection with *E. canis* is immunosuppressive therefore a wide variety of other co-morbidities may be present.

**Laboratory abnormalities**

Blood tests (haematology, serum biochemistry) and urine analysis are indicated to investigate the systemic signs of illness, bleeding diatheses and weight loss. Regardless of the stage of infection, most (if not all) dogs have thrombocytopenia, which can range from moderate to severe. In fact, dogs with a normal

Infection with Ehrlichia canis (Ehrlichiosis)

Platelet count are very unlikely to have CME. Veterinarians suspecting ehrlichiosis are encouraged to make and examine blood smears to confirm the presence of thrombocytopenia.

Laboratory abnormalities associated with ehrlichiosis include:

- Thrombocytopenia (moderate to severe)
- Leucocytosis (early), leucopenia (late)
- Monocytosis
- Lymphocytosis (early), lymphopenia (late)
- Anaemia (mild to severe in late infection)
- Pancytopenia (late)
- Hyperglobulinaemia
- Hypoalbuminaemia
- Mild elevations in liver enzyme activities
- Mild to moderate azotaemia

Dark-staining clusters of bacteria (morulae) may be observed as intracytoplasmic inclusions in monocytes during early stages of infection, however this is sufficiently rare to be a reliable diagnostic indicator.

**Differential diagnosis**

The clinical signs above are non-specific and occur in many systemic diseases of an infectious and/or inflammatory nature, including immune-mediated diseases and neoplasia. Differential diagnoses may include anaplasmosis, babesiosis, lymphoma, multiple myeloma and immune-mediated thrombocytopenia.

**Veterinarians should consider infection with E. canis in sick dogs with a history of tick exposure, especially in the absence of effective prevention of tick attachment.**

**Disease progression**

Dogs infected recently may show a combination of signs, or the infection may go unnoticed, after which a period of asymptomatic (sub-clinical) infection lasts for several months, or potentially even years.

Later (chronic) stages of infection are associated with clinical signs and laboratory abnormalities of increasing severity and tend to be terminal in their outcome. As the infection progresses, a range of immune-complex pathologies including vasculitis, uveitis and glomerulonephritis develop as a consequence of excessive immunoglobulin production, however these antibodies are non-protective. Polyclonal and (less commonly) monoclonal gammopathies are noted and terminal bone marrow failure is associated with pancytopenia and sepsis.

**Notification**

Infection with *E. canis* is a notifiable animal disease in the NT, and any person who suspects or confirms a case must report it to the **Emergency Animal Disease Watch Hotline 1800 675 888**.

**Sample collection and testing**

Suspect cases will be tested free of charge at the Berrimah Veterinary Laboratory on a weekly basis. Please contact specimen reception on 08 8999 2249 or bvl@nt.gov.au to notify of incoming samples and confirm testing days.

**Testing for notifiable diseases, including infection with E. canis, must not be performed in-house in veterinary clinics or at non-government veterinary laboratories.**

The best means of diagnosis of CME is combined PCR and serology. Suitable specimens for laboratory testing include:
Infection with Ehrlichia canis (Ehrlichiosis)

- EDTA blood (ideally at least 2mL) for detection of bacterial DNA by polymerase chain reaction (PCR) testing; AND
- Whole blood or serum (ideally at least 2ml) for antibody testing (serology) by enzyme-linked immunosorbent assay (ELISA). Sample may be centrifuged to obtain serum only, particularly if there is likely to be a delay in arrival at the laboratory.

There is no value in submitting tick samples for ehrlichiosis testing.

Samples should be sent to Berrimah Veterinary Laboratory - Department of Industry, Tourism and Trade, 29 Makagon Road, Berrimah NT 0828. A completed specimen advice note must accompany all submissions.

Interpretation of results

Patient infection status should be interpreted based on laboratory results, clinical signs and response to previous treatment. The following matrix may be used as a guide:

<table>
<thead>
<tr>
<th>PCR test result</th>
<th>Serology ELISA test result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Acute Infection</td>
</tr>
<tr>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>Acute Infection</td>
</tr>
<tr>
<td></td>
<td>Subacute/chronic infection or recovered</td>
</tr>
<tr>
<td></td>
<td>Not infected</td>
</tr>
</tbody>
</table>

Where results are indeterminate or borderline, resampling and retesting at least 14 days from first sample collection is recommended. Persistently borderline antibody results can be tested with a referral quantitative immunofluorescent antibody test (IFAT) as fee for service.

Positive PCR results indicate that there is detectable DNA of the target organism within the sample tested. It should be noted that acute infections are more likely to result in PCR positive blood samples, and that PCR may be negative in subacute or chronic cases of CME as the organism may be present in circulation at very low (undetectable) levels, or be sequestered in tissue (spleen or bone marrow). The current PCR diagnostic sensitivity and specificity for E. canis is estimated to be greater than 90%.

Serology ELISA is a non-quantitative test which detects host antibody to E. canis. Antibody may take 2-3 weeks to develop from the time of infection, and this is also the usual time period for clinical signs to develop; therefore, acute, subacute, chronic and recovered infections are likely to result in ELISA positive results. The longevity of antibody varies between individuals but may remain at detectable levels for years after infection. A single antibody titre result does not indicate where in the disease process the animal is. The diagnostic sensitivity and specificity of this test is estimated at 95% sensitivity and 97% specificity.

Case management

Treatment

This section has been generously provided by Emeritus Professor Peter Irwin of the School of Veterinary Medicine, Murdoch University.

**Doxycycline at 10mg/kg q24h (or 5mg/kg q12h) PO, for 28 days is the recommended treatment for CME.**

The stage of infection in a patient is not always clear in clinical situations, and cases treated later in the course of infection do not appear to respond so well; this can result in persistent infections and apparent failures in antimicrobial efficacy. The reason for this is not clear but may be associated with bacterial sequestration in the spleen and/or bone marrow. The earlier the infection can be treated the better the likely outcome.

Most other antibiotics are ineffective, however rifampicin at 15mg/kg PO q12h for 7 days appears to be efficacious in limited studies and would be a suitable choice if doxycycline fails to clear infection. Imidocarb dipropionate, also used to treat babesiosis, was at a dose of 5-6mg/kg IM, repeated 14 days later, although recent literature reports reduced efficacy for CME.

The other main consideration during treatment of CME is to manage the immune-complex pathology, described above, which itself can cause significant morbidity. A short (7-10 day) course of prednisolone at anti-inflammatory dose (1mg/kg q24h PO), although untested in controlled studies, appears to help recovery and reduce complications associated with CME.

Supportive treatments (e.g. blood transfusion, fluid therapy) may be considered as indicated, however chronic ehrlichiosis associated with pancytopenia carries a grave prognosis and recovery is unlikely.

**Response to treatment**

Unfortunately there is no straightforward test to monitor treatment success. A positive PCR test post treatment may indicate the dog is still bacteraemic and treatment was unsuccessful, however, given the ability of the organism to sequester in tissues and be absent from circulation, a negative result does not indicate if the dog has successfully cleared the infection. Similarly serology ELISA after treatment is not useful, as antibody titres can be expected to stay high for months to years after treatment.

**Additional recommendations**

Dogs with suspected or confirmed ehrlichiosis should be immediately treated with a registered systemic acaricide, even where there is no visible tick burden. The owner should be informed of the future disease risk to other dogs, including the need to maintain the dog on long term effective tick control, and advised to consider treatment of the dog’s home environment by a pest controller.

Owners should be provided with a copy of the Factsheet [Ehrlichiosis: treatment for your dog](https://nt.gov.au/__data/assets/pdf_file/0005/899501/ecanis-treatment-for-your-dog-information-sheet.pdf).

**Movement controls**

Dogs with suspected or confirmed ehrlichiosis, or pending test results, may not be allowed to move interstate. Owners should be advised to check with the state biosecurity body of their destination prior to moving their dog.
Infection with Ehrlichia canis (Ehrlichiosis)

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Further information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Queensland</td>
<td>See Biosecurity Queensland website(^4) or call 13 25 23.</td>
</tr>
<tr>
<td>Western Australia</td>
<td>See WA Department of Primary Industries and Regional Development website(^4) or call (08) 9368 3929</td>
</tr>
<tr>
<td>South Australia</td>
<td>See SA Department of Primary Industries and Regions website(^4)</td>
</tr>
<tr>
<td>Victoria</td>
<td>See Agriculture Victoria website(^2) or call 136 186</td>
</tr>
<tr>
<td>New South Wales</td>
<td>See NSW Department of Primary Industries website(^8)</td>
</tr>
<tr>
<td>Australian Capital Territory</td>
<td>Call the Biosecurity Veterinary Officer on 13 22 81</td>
</tr>
<tr>
<td>Tasmania</td>
<td>See Biosecurity Tasmania website(^9) or call 1300 368 550</td>
</tr>
</tbody>
</table>

Prevention

In relation to *E. canis* there are two major categories of acaricides for dogs:

- **Oral and systemic isoxazoline products.** These products require the tick to feed prior to kill, with the time from attachment to kill from 8 to 48 hours. As such, they are not registered for the prevention of canine tick-borne diseases present in Australia

- **Repel and kill products** (eg. flumethrin, permethrin). These products adhere to fur and fatty layers and are effective immediately upon contact, repelling up to 95% of ticks from infesting the dog. Two products have been shown to be efficacious for the prevention of canine ehrlichiosis (Seresto®, Advantix®)

A summary of acaricidal options for dogs is provided below, however please note this list is not exhaustive and there may be additional registered products available.

<table>
<thead>
<tr>
<th>Acaricide type</th>
<th>Active acaricide</th>
<th>Brand name</th>
<th>Route</th>
<th>Frequency of administration</th>
<th>&gt;90% proven efficacy for prevention of ehrlichiosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoxazoline</td>
<td>Sarolaner</td>
<td>Simparica (Zoetis)</td>
<td>Oral</td>
<td>Monthly</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Afoxolaner</td>
<td>Nexguard (Boehringer Ingelheim)</td>
<td>Oral</td>
<td>Monthly</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Fluralaner</td>
<td>Bravecto (Intervet)</td>
<td>Topical or oral</td>
<td>3-monthly</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Lotilaner</td>
<td>Credelio (Elanco)</td>
<td>Oral</td>
<td>Monthly</td>
<td>No</td>
</tr>
<tr>
<td>Repel and kill</td>
<td>Flumethrin</td>
<td>Seresto (Bayer-Elanco)</td>
<td>Collar</td>
<td>8-monthly</td>
<td>Yes(^{10})</td>
</tr>
<tr>
<td></td>
<td>Permethrin</td>
<td>Advantix (Bayer-Elanco)</td>
<td>Spot-on</td>
<td>Monthly</td>
<td>Yes(^{11})</td>
</tr>
<tr>
<td></td>
<td>Delamethrin</td>
<td>Scalibor (Intervet)</td>
<td>Collar</td>
<td>6-monthly</td>
<td>No</td>
</tr>
</tbody>
</table>

---


\(^{5}\) https://www.agric.wa.gov.au/ehrlichiosis


The combined use of a repel and kill product and a systemic isoxazoline may provide broader spectrum protection for an individual dog, reduce individual tick burden and minimise the spread of disease.

In summary, it is recommended that dog owners use an integrated tick control strategy which includes:

- Keeping dogs up to date a tick control program which includes registered tick repellents (primary protection) and tick control products (secondary protection).
- Avoiding taking dogs into tick-infested areas.
- Having any tick infestations in the house or yard managed by a pest controller.
- Inspecting dogs daily for ticks, especially if they have been in a tick-infested areas.